Global Cancer Observatory. Cancer today. 2023. https://gco.iarc.fr/. Accessed 18 Jan 2024.

Liu XL, Deng JW, Yuan Y, et al. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239: 108296.

Article  CAS  PubMed  Google Scholar 

Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95.

Article  CAS  PubMed  Google Scholar 

Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines®): breast cancer (version 5.2023). 2023. https://www.nccn.org. Accessed 18 Jan 2024.

Rugo H, Bardia A, Marmé F, et al. Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+/HER2- metastatic breast cancer (mBC) [abstract no. GS1-11 plus presentation]. Cancer Res. 2023;83(5 Suppl.):GS1–11.

Google Scholar 

Gilead Sciences Inc. TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use: US prescribing information. 2023. https://www.accessdata.fda.gov. Accessed 18 Jan 2024.

Gilead Sciences Inc. Trodelvy 200 mg powder for concentrate for solution for infusion: EU summary of product characteristics. 2023. https://www.ema.europa.eu. Accessed 18 Jan 2024.

Gilead Sciences Canada Inc. TRODELVY® sacituzumab govitecan 180 mg lyophilized powder for solution for injection, for intravenous use: Canadian prescribing information. 2023. https://www.gilead.ca. Accessed 18 Jan 2024.

Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10):1019–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709–18.

Article  CAS  PubMed  Google Scholar 

Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17(10):3157–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sathe A, Singh I, Jones A, et al. Population pharmacokinetics (popPK) of sacituzumab govitecan (SG) in patients (pts) with locally advanced or metastatic breast cancer (mBC) or other solid tumors [abstract no. PII-082]. Clin Pharmacol Ther. 2023;113(Suppl. 1):S70.

Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365–76.

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Marmé F, et al. Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study [abstract no. 214MO plus presentation]. Ann Oncol. 2022;33(Suppl. 7):S635–6.

Article  Google Scholar 

Bardia A, Rugo HS, Cortes J, et al. Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2- metastatic breast cancer (mBC): biomarker results from the phase 3 TROPiCS-02 study [abstract no. 1082 plus poster]. J Clin Oncol. 2023;41(16 Suppl.):1082.

Article  Google Scholar 

Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423–33.

Article  CAS  PubMed  Google Scholar 

Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) [abstract no. 1003]. J Clin Oncol. 2023;41(16 Suppl.):1003.

Article  Google Scholar 

Rugo H, Schmid P, Tolaney S, et al. Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC) [abstract no. 1553O plus presentation]. Ann Oncol. 2022;33(Suppl. 7):S1258.

Article  Google Scholar 

Tolaney S, Schmid P, Bardia A, et al. Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in HR+/HER2- metastatic breast cancer (MBC) [abstract no. P3-07-08 plus poster]. Cancer Res. 2023;83(5 Suppl.).

Marmé F, Rugo HS, Tolaney SM, et al. Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC) [abstract no. 194P]. ESMO Open. 2023;8(1): 101383.

Article  Google Scholar 

Shi DM, Li Y, Liang XY, et al. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Front Oncol. 2023. https://doi.org/10.3389/fonc.2023.1162360.

Article  PubMed  PubMed Central  Google Scholar